BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22247356)

  • 1. Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome.
    Grika EP; Ziakas PD; Zintzaras E; Moutsopoulos HM; Vlachoyiannopoulos PG
    J Rheumatol; 2012 Mar; 39(3):516-23. PubMed ID: 22247356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High impact of antiphospholipid syndrome on irreversible organ damage and survival of patients with systemic lupus erythematosus.
    Ruiz-Irastorza G; Egurbide MV; Ugalde J; Aguirre C
    Arch Intern Med; 2004 Jan; 164(1):77-82. PubMed ID: 14718326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus.
    Danowski A; de Azevedo MN; de Souza Papi JA; Petri M
    J Rheumatol; 2009 Jun; 36(6):1195-9. PubMed ID: 19447935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.
    Bertolaccini ML; Atsumi T; Escudero Contreras A; Khamashta MA; Hughes GR
    J Rheumatol; 2001 Dec; 28(12):2637-43. PubMed ID: 11764209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus.
    Somers E; Magder LS; Petri M
    J Rheumatol; 2002 Dec; 29(12):2531-6. PubMed ID: 12465147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients.
    Cervera R; Serrano R; Pons-Estel GJ; Ceberio-Hualde L; Shoenfeld Y; de Ramón E; Buonaiuto V; Jacobsen S; Zeher MM; Tarr T; Tincani A; Taglietti M; Theodossiades G; Nomikou E; Galeazzi M; Bellisai F; Meroni PL; Derksen RH; de Groot PG; Baleva M; Mosca M; Bombardieri S; Houssiau F; Gris JC; Quéré I; Hachulla E; Vasconcelos C; Fernández-Nebro A; Haro M; Amoura Z; Miyara M; Tektonidou M; Espinosa G; Bertolaccini ML; Khamashta MA;
    Ann Rheum Dis; 2015 Jun; 74(6):1011-8. PubMed ID: 24464962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome.
    Tektonidou MG; Sotsiou F; Nakopoulou L; Vlachoyiannopoulos PG; Moutsopoulos HM
    Arthritis Rheum; 2004 Aug; 50(8):2569-79. PubMed ID: 15334471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and pattern of antiphospholipid antibody syndrome in a hospital based longitudinal study of 193 patients of systemic lupus erythematosus.
    Singh NK; Agrawal A; Singh MN; Kumar V; Godhra M; Gupta A; Yadav DP; Usha ; Singh RG; Singh TB
    J Assoc Physicians India; 2013 Sep; 61(9):623-6. PubMed ID: 24772699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Subclinical and clinical manifestations of atherosclerosis in antiphospholipid syndrome].
    Reshetniak TM; Seredavkina nV; Mach ES; Aleksandrova EN; Novikov AA; Cherkasova MV; Nasonov EL
    Ter Arkh; 2008; 80(10):60-7. PubMed ID: 19105418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and clinical significance of antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome.
    Muñoz-Rodríguez FJ; Reverter JC; Font J; Tàssies D; Cervera R; Espinosa G; Carmona F; Balasch J; Ordinas A; Ingelmo M
    Haematologica; 2000 Jun; 85(6):632-7. PubMed ID: 10870121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombovascular events affect quality of life in patients with systemic lupus erythematosus.
    Balitsky AK; Peeva V; Su J; Aghdassi E; Yeo E; Gladman DD; Urowitz MB; Fortin PR
    J Rheumatol; 2011 Jun; 38(6):1017-9. PubMed ID: 21362766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-beta2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus.
    Danowski A; Kickler TS; Petri M
    J Rheumatol; 2006 Sep; 33(9):1775-9. PubMed ID: 16960938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predominant prevalence of arterial thrombosis in Japanese patients with antiphospholipid syndrome.
    Fujieda Y; Atsumi T; Amengual O; Odani T; Otomo K; Kato M; Oku K; Kon Y; Horita T; Yasuda S; Koike T
    Lupus; 2012 Dec; 21(14):1506-14. PubMed ID: 22936124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Antiphospholipid syndrome (APS) primary (PAPS) and secondary (SAPS)].
    Chwalińska-Sadowska H; Meissner M; Wudarski M; Zabek J; Wojciechowska B
    Pol Arch Med Wewn; 2006 May; 115(5):401-6. PubMed ID: 17195351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Risk factors for the development of thrombotic complication in patients with lupus erythematosus and lupus nephropatic].
    Zaldívar-Alcántara H; Herrera-Jiménez LE; Dehesa-López E; Correa-Rotter R
    Rev Invest Clin; 2013; 65(3):199-208. PubMed ID: 23877806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiphospholipid syndrome.
    Gezer S
    Dis Mon; 2003 Dec; 49(12):696-741. PubMed ID: 14679358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiphospholipid syndrome and recurrent thrombosis in children.
    Berkun Y; Padeh S; Barash J; Uziel Y; Harel L; Mukamel M; Revel-Vilk S; Kenet G
    Arthritis Rheum; 2006 Dec; 55(6):850-5. PubMed ID: 17139660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiphospholipid antibodies in pediatric systemic lupus erythematosus and the antiphospholipid syndrome.
    Avcin T; Silverman ED
    Lupus; 2007; 16(8):627-33. PubMed ID: 17711899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of damage progression in Portuguese patients with systemic lupus erythematosus.
    Santos MJ; Vinagre F; Nero P; Barcelos F; Barcelos A; Rodrigues AM; de Matos AA; Silva C; Miranda L; Capela S; Marques A; Branco J; da Silva JC
    Ann N Y Acad Sci; 2009 Sep; 1173():822-8. PubMed ID: 19758234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of the Charlson comorbidity index with mortality in systemic lupus erythematosus.
    Jönsen A; Clarke AE; Joseph L; Belisle P; Bernatsky S; Nived O; Bengtsson AA; Sturfelt G; Pineau CA
    Arthritis Care Res (Hoboken); 2011 Sep; 63(9):1233-7. PubMed ID: 21618451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.